JP2019522465A5 - - Google Patents

Download PDF

Info

Publication number
JP2019522465A5
JP2019522465A5 JP2018560480A JP2018560480A JP2019522465A5 JP 2019522465 A5 JP2019522465 A5 JP 2019522465A5 JP 2018560480 A JP2018560480 A JP 2018560480A JP 2018560480 A JP2018560480 A JP 2018560480A JP 2019522465 A5 JP2019522465 A5 JP 2019522465A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
acid sequence
mutant
mhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018560480A
Other languages
English (en)
Japanese (ja)
Other versions
JP7071288B2 (ja
JP2019522465A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/033187 external-priority patent/WO2017201210A1/en
Publication of JP2019522465A publication Critical patent/JP2019522465A/ja
Publication of JP2019522465A5 publication Critical patent/JP2019522465A5/ja
Application granted granted Critical
Publication of JP7071288B2 publication Critical patent/JP7071288B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018560480A 2016-05-18 2017-05-17 Ｔ細胞調節多量体ポリペプチド及びその使用方法 Active JP7071288B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338410P 2016-05-18 2016-05-18
US62/338,410 2016-05-18
PCT/US2017/033187 WO2017201210A1 (en) 2016-05-18 2017-05-17 T-cell modulatory multimeric polypeptides and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2019522465A JP2019522465A (ja) 2019-08-15
JP2019522465A5 true JP2019522465A5 (enExample) 2020-06-25
JP7071288B2 JP7071288B2 (ja) 2022-05-18

Family

ID=60326131

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560480A Active JP7071288B2 (ja) 2016-05-18 2017-05-17 Ｔ細胞調節多量体ポリペプチド及びその使用方法

Country Status (11)

Country Link
US (2) US11505591B2 (enExample)
EP (1) EP3458096A4 (enExample)
JP (1) JP7071288B2 (enExample)
KR (1) KR20190019068A (enExample)
CN (1) CN109475628A (enExample)
AU (1) AU2017268348A1 (enExample)
BR (1) BR112018073606A2 (enExample)
CA (1) CA3019005A1 (enExample)
IL (1) IL262403A (enExample)
SG (1) SG11201808552XA (enExample)
WO (1) WO2017201210A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015188839A2 (en) 2014-06-13 2015-12-17 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
KR20180132070A (ko) * 2016-03-03 2018-12-11 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US11078282B2 (en) 2016-04-15 2021-08-03 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
JP7071288B2 (ja) 2016-05-18 2022-05-18 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
MX2019007611A (es) 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
CN118453840A (zh) 2017-03-15 2024-08-09 库尔生物制药有限公司 用于调节免疫应答的方法
CN110662758A (zh) 2017-03-16 2020-01-07 高山免疫科学股份有限公司 Cd80变体免疫调节蛋白及其用途
CA3057866A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
CA3074839A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
CN109879969B (zh) * 2017-12-06 2024-04-09 天士力生物医药股份有限公司 一种hm-3融合蛋白及其应用
WO2019139896A1 (en) * 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020132136A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
TW202039541A (zh) * 2018-12-19 2020-11-01 美商庫爾生物製藥有限公司 多聚體ｔ細胞調節多肽及其使用方法
TWI856047B (zh) 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020132138A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020181273A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
JP7535273B2 (ja) * 2019-04-26 2024-08-16 スアンズ バイオファーマシューティカル カンパニー，リミテッド Ｃｄ８０バリアントタンパク質とその使用
WO2020243315A1 (en) * 2019-05-29 2020-12-03 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP3986448A4 (en) * 2019-06-19 2023-07-12 Cue Biopharma, Inc. MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
WO2021055594A1 (en) * 2019-09-20 2021-03-25 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
SK283703B6 (sk) 1993-10-25 2003-12-02 Canji, Inc. Rekombinantný adenovírusový vektor a jeho použitie
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US7098306B2 (en) 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
JP3816959B2 (ja) 1997-02-13 2006-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 肝細胞癌の予防および処置
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US20030007978A1 (en) 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6696304B1 (en) 1999-02-24 2004-02-24 Luminex Corporation Particulate solid phase immobilized protein quantitation
EP1173204B1 (en) 1999-04-30 2010-04-21 The Trustees Of The University Of Pennsylvania Mutant human cd80 and compositions for and methods of making and using the same
US20020006664A1 (en) 1999-09-17 2002-01-17 Sabatini David M. Arrayed transfection method and uses related thereto
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
CN1430728A (zh) 2000-05-25 2003-07-16 苏诺尔分子公司 T细胞受体交互作用的调节
US20020122820A1 (en) 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
US6800748B2 (en) 2001-01-25 2004-10-05 Large Scale Biology Corporation Cytoplasmic inhibition of gene expression and expression of a foreign protein in a monocot plant by a plant viral vector
AU2002240818C1 (en) 2001-03-14 2008-11-06 Agilent Technologies, Inc. MHC molecule constructs and their uses for diagnosis and therapy
AU2002309865A1 (en) 2001-05-15 2002-11-25 University Of Medicine & Dentistry Of New Jersey Methods for analyzing interactions between proteins in live and intact cells
US20040161817A1 (en) 2001-06-04 2004-08-19 Corixa Corporation Compositions and methods for high-level, large-scale production of recombinant proteins
US20030017134A1 (en) 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
AU2002368044A1 (en) 2001-06-22 2004-04-19 Maxygen, Inc. Co-stimulatory molecules
AU2002322211A1 (en) 2001-07-12 2003-01-29 Canvac Methods and compisitions for activation human t cells in vitro
AU2002363354A1 (en) 2001-07-27 2003-05-19 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
EP1599502A1 (en) 2003-02-27 2005-11-30 TheraVision GmbH A molecule which binds cd80 and cd86
AU2003901876A0 (en) 2003-04-17 2003-05-08 The Macfarlane Burnet Institute For Medical Research And Public Health Viral vector
US20050042641A1 (en) 2003-05-27 2005-02-24 Cold Spring Harbor Laboratory In vivo high throughput selection of RNAi probes
EP2783699A1 (en) 2003-09-05 2014-10-01 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
US7470513B2 (en) 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions
WO2005091956A2 (en) 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060034850A1 (en) 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
KR20080082628A (ko) 2005-11-10 2008-09-11 리셉터 바이오로직스 인크 수용체 및 리간드 이소형태의 제조 방법
EP2863222A1 (en) 2006-03-06 2015-04-22 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
MX2008014722A (es) 2006-05-19 2011-04-15 Teva Pharma Proteinas de fusion, usos de las mismas y procesos para producir las mismas.
EP1889851A1 (en) 2006-08-18 2008-02-20 Charite Universitätsmedizin-Berlin PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies
US8992937B2 (en) 2006-08-28 2015-03-31 Washington University Disulfide trap MHC class I molecules and uses therefor
NZ601175A (en) 2006-12-28 2012-12-21 Int Inst Cancer Immunology Inc Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
CN101657213B (zh) 2007-02-15 2014-02-26 曼康公司 用于增强t细胞应答的方法
WO2008113970A2 (en) 2007-03-16 2008-09-25 Ucl Business Plc Peptides
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2615172A1 (en) 2007-04-27 2013-07-17 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
US8926961B2 (en) 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
CN101418309B (zh) 2007-10-23 2011-05-04 中国农业科学院上海兽医研究所 柔嫩艾美耳球虫蛋白质二硫键异构酶基因的克隆、表达及应用
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
EP2184070A1 (en) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
AU2010206840B2 (en) 2009-01-21 2015-02-05 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
EP2445935B1 (en) 2009-06-25 2015-07-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
EP3851459B1 (en) 2010-09-21 2024-05-01 Altor BioScience, LLC Multimeric il-15 soluble fusion molecules and methods of making and using same
JP6093712B2 (ja) 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
KR102038155B1 (ko) 2011-06-22 2019-10-29 에프. 호프만-라 로슈 아게 Mhc 클래스 i 포함 복합체를 사용한 순환 바이러스-특이적 세포독성 t-세포에 의한 표적 세포의 제거
CN107988156B (zh) 2011-06-30 2022-01-04 建新公司 T细胞活化的抑制剂
DE112011100879A5 (de) 2011-08-30 2013-11-14 Jacobs University Bremen Ggmbh Gen codiert für ein MHC-Klasse-I-Molekül, Plasmid, Expressionssystem, Protein, Multimer, Reagenz und Kit zum Analysieren einer T-Zellen-Frequenz
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
HK1204261A1 (en) 2012-01-13 2015-11-13 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
EP2809345A4 (en) 2012-02-03 2015-11-25 Univ Emory IMMUNOSTIMULATING COMPOSITIONS, PARTICLES THEREFOR, AND USES THEREFOR
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
BR112015011111A2 (pt) 2012-11-30 2017-11-14 Roche Glycart Ag proteína multifuncional e formulação farmacêutica
JP2016500255A (ja) 2012-12-11 2016-01-12 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ハイスループットなレセプター：リガンド同定の方法
SG11201504414UA (en) 2012-12-21 2015-07-30 Hoffmann La Roche Disulfide-linked multivalent mhc class i comprising multi-function proteins
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
DK2982681T3 (en) 2013-03-29 2018-12-10 Sumitomo Dainippon Pharma Co Ltd WT1 ANTIGENPEPTIDKONJUGATVACCINE
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
BR112016001114B1 (pt) 2013-07-19 2023-02-14 Vib Vzw Composição compreendendo uma proteína de fusão e uso da referida composição
US20170176435A1 (en) 2014-01-21 2017-06-22 Albert Einstein College Of Medicine, Inc. Cellular platform for rapid and comprehensive t-cell immunomonitoring
WO2015130766A1 (en) 2014-02-25 2015-09-03 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
KR101804343B1 (ko) 2014-02-26 2017-12-04 텔라 가부시키가이샤 Ｗｔ１ 항원성 폴리펩티드 및 상기 폴리펩티드를 포함하는 항종양제
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
JP6652932B2 (ja) * 2014-06-18 2020-02-26 アルバート アインシュタイン カレッジ オブ メディシン ｓｙｎＴａｃポリペプチド及びその使用
KR102003754B1 (ko) 2014-07-03 2019-07-25 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
MX378790B (es) 2014-07-21 2025-03-10 Delinia Inc Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
CA2957717C (en) 2014-08-12 2021-10-19 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
JP2017525370A (ja) 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法
WO2016030350A1 (en) 2014-08-29 2016-03-03 F. Hoffmann-La Roche Ag Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
ES2979088T3 (es) 2015-03-05 2024-09-24 Fred Hutchinson Cancer Center Proteínas de fusión inmunomoduladoras y usos de las mismas
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US11046745B2 (en) 2015-07-14 2021-06-29 BioNTech SE Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereof
CA2993429A1 (en) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
CN106565836B (zh) 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
EP4130026A1 (en) 2015-11-20 2023-02-08 Memorial Sloan-Kettering Cancer Center Methods and compositions for treating cancer
US20190365656A1 (en) 2016-01-04 2019-12-05 Cour Pharmaceuticals Development Company, Inc. Particles encapsulating fusion proteins containing linked epitopes
US20190062400A1 (en) * 2016-03-02 2019-02-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20180132070A (ko) 2016-03-03 2018-12-11 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
CN109071623B (zh) 2016-05-04 2022-05-27 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
JP7071288B2 (ja) 2016-05-18 2022-05-18 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
MX2019007611A (es) * 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
EP3565829A4 (en) * 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
CN118453840A (zh) * 2017-03-15 2024-08-09 库尔生物制药有限公司 用于调节免疫应答的方法
WO2019051126A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
AU2018328283A1 (en) * 2017-09-07 2020-02-20 Cue Biopharma, Inc. Antigen-presenting polypeptides and methods of use thereof
BR112020004535A2 (pt) * 2017-09-07 2020-09-08 Cue Biopharma, Inc. peptídeos moduladores de células t multiméricos e métodos de uso destes
CA3074839A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
WO2019139896A1 (en) * 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
TW202039541A (zh) * 2018-12-19 2020-11-01 美商庫爾生物製藥有限公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020132136A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020132368A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020243315A1 (en) * 2019-05-29 2020-12-03 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP3986448A4 (en) * 2019-06-19 2023-07-12 Cue Biopharma, Inc. MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
WO2021081239A1 (en) * 2019-10-23 2021-04-29 Cue Biopharma, Inc. T-cell modulatory chimeric molecules and methods of use thereof
WO2021195108A1 (en) * 2020-03-24 2021-09-30 Cue Biopharma, Inc. T cell modulatory polypeptides and methods of use thereof
TW202208395A (zh) * 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2021242935A1 (en) * 2020-05-26 2021-12-02 Cue Biopharma, Inc. Antigen presenting polypeptide complexes and methods of use thereof
EP4157350A4 (en) * 2020-05-26 2025-07-23 Cue Biopharma Inc ANTIGEN-PRESENTING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF
CN113823723A (zh) 2020-06-18 2021-12-21 光宝光电(常州)有限公司 发光二极管封装结构
IL299834A (en) * 2020-07-14 2023-03-01 Cue Biopharma Inc with binding sites and methods for using them T - cellular modulatory polypeptides
WO2022099157A1 (en) * 2020-11-06 2022-05-12 Cue Biopharma, Inc. Antigen presenting polypeptide complexes and methods of use thereof
CA3174142A1 (en) * 2020-11-06 2022-05-12 Ronald D. Seidel Iii T-cell modulatory polypeptides with conjugation sites and methods of use thereof
CN117561280A (zh) * 2021-04-21 2024-02-13 库尔生物制药有限公司 携带TGF-β的抗原呈递多肽复合物及其使用方法
US20240270815A1 (en) * 2021-05-26 2024-08-15 Cue Biopharma, Inc. Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
WO2023137158A2 (en) * 2022-01-13 2023-07-20 Cue Biopharma, Inc. T cell modulatory polypeptides with conjugation sites and methods of use thereof
WO2023137156A2 (en) * 2022-01-13 2023-07-20 Cue Biopharma, Inc. T cell modulatory polypeptides with conjugation sites and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2019522465A5 (enExample)
JP2019522466A5 (enExample)
JP2019516665A5 (enExample)
JP2019512222A5 (enExample)
JP2020511949A5 (enExample)
JP2017527272A5 (enExample)
JP2019501647A5 (enExample)
JP2021500855A5 (enExample)
JP2017512063A5 (enExample)
IL308851B2 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
JP2018515085A5 (enExample)
RU2017135596A (ru) Слитый полипептид с противораковой активностью
JP2018524326A5 (enExample)
JP2020529841A5 (enExample)
JP2017509335A5 (enExample)
IL275307A (en) SYNTAC polypeptides and their uses
JP2017519491A5 (enExample)
JP2017527310A5 (enExample)
IL272085B (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2015212284A5 (enExample)
FI3294333T4 (fi) Klaudiini-18.2-spesifiset immunoreseptorit ja t-soluepitoopit
JP2020500015A5 (enExample)
FI3434767T3 (fi) Sytotoksisuutta aiheuttava terapeuttinen aine
MX2020011391A (es) Anticuerpo bcma humanizado y linfocitos t car-bcma.
FI3665192T3 (fi) Muunneltuja transferriinireseptoria sitovia polypeptidejä